Arterial chemoembolization with mitomycin C microcapsules followed by transcatheter hepatic artery embolization for hepatocellular carcinoma.
Arterial chemoembolization with mitomycin C microcapsules followed by transcatheter hepatic artery embolization for hepatocellular carcinoma.
复制标题
丝裂霉素C微胶囊动脉化疗栓塞随后经导管肝动脉栓塞治疗肝细胞癌。
DOI：
--
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
Y. Tanabe
中科院分区：
文献类型：
--
作者：
K. Ohnishi;S. Sugita;F. Nomura;S. Iida;Y. Tanabe
66例肝细胞癌患者中，32例采用动脉注射丝裂霉素C微胶囊（A组），34例患者采用动脉注射丝裂霉素C微胶囊并经导管肝动脉栓塞术（B组）。肝脏图像上可测量的肿瘤消退面积大于 50%，A 组有 28%，B 组有 57%（p 小于 0.05）。 A 组中 59% 的患者和 B 组中 91% 的患者血清甲胎蛋白降低至初始水平的一半以下（p 小于 0.05）。 B组的生存率优于A组（p小于0.05）。这些结果表明，丝裂霉素C微胶囊动脉化疗栓塞联合经导管肝动脉栓塞治疗肝细胞癌将比单独丝裂霉素C微胶囊动脉化疗栓塞治疗有所改善。
Of 66 patients with hepatocellular carcinoma, 32 were treated by intraarterial injection of mitomycin C microcapsules (group A) and 34 patients by intraarterial injection of mitomycin C microcapsules followed by transcatheter hepatic artery embolization (group B). Measurable tumor regression greater than 50% in area on liver image occurred in 28% of group A and 57% of group B (p less than 0.05). A decrease of serum alpha-fetoprotein to less than half the initial level was demonstrated in 59% of group A and 91% of group B (p less than 0.05). The survival rate was better in group B compared with group A (p less than 0.05). These results indicate that arterial chemoembolization with mitomycin C microcapsules plus transcatheter hepatic artery embolization will be an improvement over arterial chemoembolization with mitomycin C microcapsules alone in the treatment of hepatocellular carcinoma.